首页 > 最新文献

Digestive and Liver Disease最新文献

英文 中文
The role of gene polymorphisms in the occurrence of gastroesophageal reflux disease: A systematic review and meta-analysis of genetic association studies. 基因多态性在胃食管反流病发生中的作用:遗传关联研究的系统回顾和荟萃分析
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-09 DOI: 10.1016/j.dld.2025.12.014
Alexandra Argyrou, Stavros P Papadakos, Ioannis Karniadakis, Elisavet Michailidou, Stamatina Vogli, Jannis Vlachogiannakos

Background: Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal disorder with multifactorial etiology, including genetic components. Despite numerous genetic association studies (GAS), the role of specific gene polymorphisms in GERD susceptibility remains unclear due to inconsistent findings.

Aims: To systematically review GAS on GERD and conduct a meta-analysis to evaluate the association between specific gene polymorphisms and GERD risk.

Methods: A systematic review of PubMed, Cochrane, ScienceDirect, Scopus, DisGENET, GWASCatalog, and HuGE Phenopedia databases (2012-2024) was conducted to identify GAS for GERD. Meta-analytical methods were used to synthesize the results.

Results: 21 GAS, including 27,783 GERD patients and 83,857 controls, were analyzed, focusing on 132 polymorphisms across 105 genes. Meta-analysis of seven studies revealed a significant association between GNB3 rs5443 C > T and increased GERD-like symptom phenotypes (ORp = 2.24, 95 % CI: 1.56-3.21), suggesting a dominant genetic model. No significant associations were found for TNF, IL1B, or CYP2C19. Heterogeneity and potential bias were observed in some analyses, necessitating cautious interpretation of the findings.

Conclusion: The findings support a robust association between GNB3 rs5443 C > T and susceptibility to GERD-like symptom phenotypes, suggesting a potential genetic predisposition. Additional large, well-characterized studies using standardized GERD definitions are needed to validate these results and elucidate the broader genetic landscape of the disease.

背景:胃食管反流病(GERD)是一种常见的多因素胃肠道疾病,其病因包括遗传因素。尽管有大量的遗传关联研究(GAS),但由于研究结果不一致,特定基因多态性在GERD易感性中的作用仍不清楚。目的:系统回顾GAS对GERD的影响,并进行荟萃分析,评估特定基因多态性与GERD风险之间的关系。方法:对PubMed、Cochrane、ScienceDirect、Scopus、DisGENET、GWASCatalog和HuGE Phenopedia数据库(2012-2024)进行系统评价,以确定GERD的GAS。采用元分析方法对结果进行综合分析。结果:共分析了21例GAS,包括27,783例GERD患者和83,857例对照,重点分析了105个基因的132个多态性。7项研究的荟萃分析显示,GNB3 rs5443 C > T与增加的gerd样症状表型之间存在显著相关性(ORp = 2.24, 95% CI: 1.56-3.21),提示存在显性遗传模型。TNF、IL1B或CYP2C19未发现显著相关性。在一些分析中观察到异质性和潜在偏倚,需要谨慎解释研究结果。结论:研究结果支持GNB3 rs5443 C > T与对gerd样症状表型的易感性之间的强相关性,提示潜在的遗传易感性。需要使用标准化GERD定义的其他大型、特征明确的研究来验证这些结果并阐明该疾病更广泛的遗传格局。
{"title":"The role of gene polymorphisms in the occurrence of gastroesophageal reflux disease: A systematic review and meta-analysis of genetic association studies.","authors":"Alexandra Argyrou, Stavros P Papadakos, Ioannis Karniadakis, Elisavet Michailidou, Stamatina Vogli, Jannis Vlachogiannakos","doi":"10.1016/j.dld.2025.12.014","DOIUrl":"10.1016/j.dld.2025.12.014","url":null,"abstract":"<p><strong>Background: </strong>Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal disorder with multifactorial etiology, including genetic components. Despite numerous genetic association studies (GAS), the role of specific gene polymorphisms in GERD susceptibility remains unclear due to inconsistent findings.</p><p><strong>Aims: </strong>To systematically review GAS on GERD and conduct a meta-analysis to evaluate the association between specific gene polymorphisms and GERD risk.</p><p><strong>Methods: </strong>A systematic review of PubMed, Cochrane, ScienceDirect, Scopus, DisGENET, GWASCatalog, and HuGE Phenopedia databases (2012-2024) was conducted to identify GAS for GERD. Meta-analytical methods were used to synthesize the results.</p><p><strong>Results: </strong>21 GAS, including 27,783 GERD patients and 83,857 controls, were analyzed, focusing on 132 polymorphisms across 105 genes. Meta-analysis of seven studies revealed a significant association between GNB3 rs5443 C > T and increased GERD-like symptom phenotypes (ORp = 2.24, 95 % CI: 1.56-3.21), suggesting a dominant genetic model. No significant associations were found for TNF, IL1B, or CYP2C19. Heterogeneity and potential bias were observed in some analyses, necessitating cautious interpretation of the findings.</p><p><strong>Conclusion: </strong>The findings support a robust association between GNB3 rs5443 C > T and susceptibility to GERD-like symptom phenotypes, suggesting a potential genetic predisposition. Additional large, well-characterized studies using standardized GERD definitions are needed to validate these results and elucidate the broader genetic landscape of the disease.</p>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapidly progressive EBV-positive DLBCL arising from a duodenal diverticulum. 由十二指肠憩室引起的快速进展的ebv阳性DLBCL。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-09 DOI: 10.1016/j.dld.2025.12.024
Hironobu Takedomi, Moeko Shirozu, Takuya Shimamura, Motohiro Esaki
{"title":"Rapidly progressive EBV-positive DLBCL arising from a duodenal diverticulum.","authors":"Hironobu Takedomi, Moeko Shirozu, Takuya Shimamura, Motohiro Esaki","doi":"10.1016/j.dld.2025.12.024","DOIUrl":"https://doi.org/10.1016/j.dld.2025.12.024","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Excellent outcomes of living donor liver transplantation: A contemporary report from Western Center. 活体肝移植的良好结果:一份来自西方中心的当代报告。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-08 DOI: 10.1016/j.dld.2025.12.015
Stefano Di Sandro, Barbara Catellani, Roberta Odorizzi, Daniela Caracciolo, Samuele Frassoni, Vincenzo Bagnardi, Cristiano Quintini, Cristiano Guidetti, Paolo Magistri, Leonardo Centonze, Gian Piero Guerrini, Charles Miller, Antonio D Pinna, Fabrizio Di Benedetto

Background and aims: Living donor liver transplantation (LDLT) helps address organ shortages but remains complex, particularly in Western countries where deceased donor liver transplantation (DDLT) is preferred. This study evaluates improvements in LDLT outcomes over time for both donors and recipients.

Study design: A single-center retrospective analysis from 2001-2023 including two periods: P-ONE (2001-2003, 36 cases) and P-TWO (2020-2023, 27 cases). Donor surgery after October 2022 marked the shift to a full robotic approach. Recipient procedures preserved the retro-hepatic vena cava, with standard vascular and biliary reconstruction. Comparisons include demographics, complications, and survival.

Results: P-ONE donors were younger (median age 32 vs. 46, P=0.003), while P-TWO recipients were older (63 vs. 56 years, P=0.005) with more comorbidities. P-TWO had more cases of hepatocellular carcinoma and low-MELD cirrhosis. Donor safety improved in P-TWO, with similar major complication rates (14% vs. 11%). Recipients in P-TWO had fewer severe complications (7% vs. 81%, P<0.001) and better 3-year graft survival.

Conclusions: Advances in patient selection, minimally invasive surgery, and perioperative care have significantly improved LDLT outcomes. Despite persistent biliary challenges, LDLT remains a promising solution for end-stage liver disease and liver cancer.

背景和目的:活体供肝移植(LDLT)有助于解决器官短缺问题,但仍然很复杂,特别是在西方国家,死者供肝移植(DDLT)是首选。本研究评估了LDLT供体和受体结果随时间的改善情况。研究设计:2001-2023年单中心回顾性分析,包括两个时期:P-ONE(2001-2003年,36例)和P-TWO(2020-2023年,27例)。2022年10月之后的供体手术标志着向全机器人方法的转变。受体手术保留了肝后腔静脉,并进行了标准血管和胆道重建。比较包括人口统计学、并发症和生存率。结果:P- one供者较年轻(中位年龄32岁对46岁,P=0.003),而P- two供者年龄较大(63岁对56岁,P=0.005),合并症较多。P-TWO组肝细胞癌和低meld肝硬化较多。P-TWO组供者安全性提高,主要并发症发生率相似(14%对11%)。结论:患者选择、微创手术和围手术期护理的进步显著改善了LDLT预后。尽管存在胆道方面的挑战,LDLT仍然是治疗终末期肝病和肝癌的一个有希望的解决方案。
{"title":"Excellent outcomes of living donor liver transplantation: A contemporary report from Western Center.","authors":"Stefano Di Sandro, Barbara Catellani, Roberta Odorizzi, Daniela Caracciolo, Samuele Frassoni, Vincenzo Bagnardi, Cristiano Quintini, Cristiano Guidetti, Paolo Magistri, Leonardo Centonze, Gian Piero Guerrini, Charles Miller, Antonio D Pinna, Fabrizio Di Benedetto","doi":"10.1016/j.dld.2025.12.015","DOIUrl":"https://doi.org/10.1016/j.dld.2025.12.015","url":null,"abstract":"<p><strong>Background and aims: </strong>Living donor liver transplantation (LDLT) helps address organ shortages but remains complex, particularly in Western countries where deceased donor liver transplantation (DDLT) is preferred. This study evaluates improvements in LDLT outcomes over time for both donors and recipients.</p><p><strong>Study design: </strong>A single-center retrospective analysis from 2001-2023 including two periods: P-ONE (2001-2003, 36 cases) and P-TWO (2020-2023, 27 cases). Donor surgery after October 2022 marked the shift to a full robotic approach. Recipient procedures preserved the retro-hepatic vena cava, with standard vascular and biliary reconstruction. Comparisons include demographics, complications, and survival.</p><p><strong>Results: </strong>P-ONE donors were younger (median age 32 vs. 46, P=0.003), while P-TWO recipients were older (63 vs. 56 years, P=0.005) with more comorbidities. P-TWO had more cases of hepatocellular carcinoma and low-MELD cirrhosis. Donor safety improved in P-TWO, with similar major complication rates (14% vs. 11%). Recipients in P-TWO had fewer severe complications (7% vs. 81%, P<0.001) and better 3-year graft survival.</p><p><strong>Conclusions: </strong>Advances in patient selection, minimally invasive surgery, and perioperative care have significantly improved LDLT outcomes. Despite persistent biliary challenges, LDLT remains a promising solution for end-stage liver disease and liver cancer.</p>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining safe thresholds for risk-adapted surveillance after liver transplantation for hepatocellular carcinoma 确定肝癌肝移植后风险适应监测的安全阈值。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-04 DOI: 10.1016/j.dld.2025.12.021
Pedro Robson Costa Passos , Danilo Dias Avancini Viana , Gabriel Gomes de Araújo Chollet , Angel Evangelista Barroso Magalhães , Clebia Azevedo de Lima , Bartolomeu Alves Neto , Rodrigo Motta , Paulo Everton Garcia Costa , Elodie Bomfim Hyppolito , Gustavo Rego Coelho , José Huygens Parente Garcia

Background

Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a major concern, but it is unclear whether existing models can safely “rule out” patients from intensive imaging strategies.

Methods

We retrospectively studied 493 LT recipients transplanted for HCC (2002–2023). Competing-risk Fine–Gray regression with bootstrap stability selection was used to derive an illustrative score and compared with established models. Rule-out performance was evaluated by 5-year cumulative incidence. Decision curve analysis (DCA) and surveillance simulations quantified trade-offs between CT scans saved and recurrences missed under reduced protocols.

Results

Our model identified total tumor diameter, microvascular invasion, satellite nodules, and log(AFP) as stable predictors. DCA showed all models outperformed uniform surveillance only when 5-year recurrence exceeded 4%, with 7.5% as the upper acceptable threshold. Within this range, low-risk groups across models had 5-year recurrence risks of 2.5–5.7%. Reduced-intensity strategies could save 160–856 CTs per 100 patients while missing ≤1 recurrence with semiannual or annual two-year protocols. Cost–benefit analysis supported 4–7.5% as the optimal threshold. False negatives were uncommon (n = 13), with only two patients misclassified by all models.

Conclusions

Widely used models can identify patients suitable for reduced surveillance, though none delineated a true “no-screening” group.
背景:肝移植(LT)后肝细胞癌(HCC)的复发是一个主要问题,但目前尚不清楚现有模型是否可以安全地“排除”患者的强化影像学策略。方法:我们回顾性研究了493例肝细胞癌肝移植受体(2002-2023)。采用带自举稳定性选择的竞争风险细灰色回归得到一个说明性分数,并与已建立的模型进行比较。以5年累计发病率评价排除效果。决策曲线分析(DCA)和监测模拟量化了在简化方案下节省的CT扫描和错过的复发之间的权衡。结果:我们的模型确定了肿瘤总直径、微血管侵袭、卫星结节和log(AFP)是稳定的预测因子。DCA显示,所有模型只有在5年复发率超过4%时才优于统一监测,最高可接受阈值为7.5%。在这个范围内,各模型中低风险组的5年复发风险为2.5-5.7%。每100名患者可减少160-856个ct,半年一次或两年一次的治疗方案可减少≤1例复发。成本效益分析支持4-7.5%为最佳阈值。假阴性不常见(n = 13),只有2例患者被所有模型错误分类。结论:广泛使用的模型可以识别适合减少监测的患者,尽管没有一个描述真正的“无筛查”组。
{"title":"Defining safe thresholds for risk-adapted surveillance after liver transplantation for hepatocellular carcinoma","authors":"Pedro Robson Costa Passos ,&nbsp;Danilo Dias Avancini Viana ,&nbsp;Gabriel Gomes de Araújo Chollet ,&nbsp;Angel Evangelista Barroso Magalhães ,&nbsp;Clebia Azevedo de Lima ,&nbsp;Bartolomeu Alves Neto ,&nbsp;Rodrigo Motta ,&nbsp;Paulo Everton Garcia Costa ,&nbsp;Elodie Bomfim Hyppolito ,&nbsp;Gustavo Rego Coelho ,&nbsp;José Huygens Parente Garcia","doi":"10.1016/j.dld.2025.12.021","DOIUrl":"10.1016/j.dld.2025.12.021","url":null,"abstract":"<div><h3>Background</h3><div>Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a major concern, but it is unclear whether existing models can safely “rule out” patients from intensive imaging strategies.</div></div><div><h3>Methods</h3><div>We retrospectively studied 493 LT recipients transplanted for HCC (2002–2023). Competing-risk Fine–Gray regression with bootstrap stability selection was used to derive an illustrative score and compared with established models. Rule-out performance was evaluated by 5-year cumulative incidence. Decision curve analysis (DCA) and surveillance simulations quantified trade-offs between CT scans saved and recurrences missed under reduced protocols.</div></div><div><h3>Results</h3><div>Our model identified total tumor diameter, microvascular invasion, satellite nodules, and log(AFP) as stable predictors. DCA showed all models outperformed uniform surveillance only when 5-year recurrence exceeded 4%, with 7.5% as the upper acceptable threshold. Within this range, low-risk groups across models had 5-year recurrence risks of 2.5–5.7%. Reduced-intensity strategies could save 160–856 CTs per 100 patients while missing ≤1 recurrence with semiannual or annual two-year protocols. Cost–benefit analysis supported 4–7.5% as the optimal threshold. False negatives were uncommon (<em>n</em> = 13), with only two patients misclassified by all models.</div></div><div><h3>Conclusions</h3><div>Widely used models can identify patients suitable for reduced surveillance, though none delineated a true “no-screening” group.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"58 2","pages":"Pages 258-264"},"PeriodicalIF":3.8,"publicationDate":"2026-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 肝病学未满足的需求:意大利肝脏研究协会(AISF)的指导。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-04 DOI: 10.1016/j.dld.2025.12.016
Stefano Gitto , Filippo Gabrielli , Giovanni Addolorato , Claudia Tarli , Giacomo Zaccherini , Rosaria Calia , Giacomo Germani , Patrizia Burra , Alberto Zanetto , Francesca Ferri , Roberta D’Ambrosio , Pierluigi Toniutto , Nicola Pugliese , Fiammetta Cosci , Giuseppe Marrone , Ciro Celsa , Lucia Craxì , Mario Masarone , Dario Saltini , Laura Turco , Paolo Caraceni
In the last decades, the world of hepatology has widely changed. Although relevant advances have be achieved (e.g. the way toward eradication of hepatitis C virus), many challenges are far to be won. Patients with liver disease continue to face noteworthy barriers to early diagnosis and effective disease management. In response to these tasks, the Italian Association for the Study of the Liver formed a multidisciplinary commission to address the unmet needs of people affected by liver diseases. We analyzed the state of the art of the following consolidated unmet needs: stigma (with particular attention to alcohol-related disease and obesity), specific criticisms of elderly, socioeconomic barriers that patients with liver disorders can face, gender gap in many aspects of liver disease and, finally, the complex issue of quality of life. For each unmet need, we proposed a key-message task and some concrete future perspectives.
Preserving a holistic vision and using both multidisciplinary and interdisciplinary method, represent the only effective approach to take on the many unmet needs of patients with liver disorders.
在过去的几十年里,肝病学的世界发生了很大的变化。虽然已经取得了相关进展(例如消灭丙型肝炎病毒的途径),但仍有许多挑战有待克服。肝病患者在早期诊断和有效的疾病管理方面仍然面临着值得注意的障碍。为了完成这些任务,意大利肝脏研究协会成立了一个多学科委员会,以解决肝病患者未得到满足的需求。我们分析了以下综合未满足需求的现状:耻辱(特别关注酒精相关疾病和肥胖),对老年人的具体批评,肝脏疾病患者可能面临的社会经济障碍,肝脏疾病许多方面的性别差距,最后,生活质量的复杂问题。对于每个未满足的需求,我们提出了一个关键消息任务和一些具体的未来前景。保持整体视野,同时采用多学科和跨学科方法,是解决肝病患者许多未满足需求的唯一有效途径。
{"title":"Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF)","authors":"Stefano Gitto ,&nbsp;Filippo Gabrielli ,&nbsp;Giovanni Addolorato ,&nbsp;Claudia Tarli ,&nbsp;Giacomo Zaccherini ,&nbsp;Rosaria Calia ,&nbsp;Giacomo Germani ,&nbsp;Patrizia Burra ,&nbsp;Alberto Zanetto ,&nbsp;Francesca Ferri ,&nbsp;Roberta D’Ambrosio ,&nbsp;Pierluigi Toniutto ,&nbsp;Nicola Pugliese ,&nbsp;Fiammetta Cosci ,&nbsp;Giuseppe Marrone ,&nbsp;Ciro Celsa ,&nbsp;Lucia Craxì ,&nbsp;Mario Masarone ,&nbsp;Dario Saltini ,&nbsp;Laura Turco ,&nbsp;Paolo Caraceni","doi":"10.1016/j.dld.2025.12.016","DOIUrl":"10.1016/j.dld.2025.12.016","url":null,"abstract":"<div><div>In the last decades, the world of hepatology has widely changed. Although relevant advances have be achieved (e.g. the way toward eradication of hepatitis C virus), many challenges are far to be won. Patients with liver disease continue to face noteworthy barriers to early diagnosis and effective disease management. In response to these tasks, the Italian Association for the Study of the Liver formed a multidisciplinary commission to address the unmet needs of people affected by liver diseases. We analyzed the state of the art of the following consolidated unmet needs: stigma (with particular attention to alcohol-related disease and obesity), specific criticisms of elderly, socioeconomic barriers that patients with liver disorders can face, gender gap in many aspects of liver disease and, finally, the complex issue of quality of life. For each unmet need, we proposed a key-message task and some concrete future perspectives.</div><div>Preserving a holistic vision and using both multidisciplinary and interdisciplinary method, represent the only effective approach to take on the many unmet needs of patients with liver disorders.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"58 2","pages":"Pages 182-196"},"PeriodicalIF":3.8,"publicationDate":"2026-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enterocyte proliferation as a new biomarker in potential coeliac disease. 肠细胞增殖作为潜在乳糜泻的新生物标志物。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-03 DOI: 10.1016/j.dld.2025.12.011
Rachele Ciccocioppo, Cinzia D'Agate, Maria Vittoria Galli, Anna Macchioni, Giuseppe Broggi, Valeria Zuliani, Luca Frulloni, Fabio Luciani, Mattia Bugatti, Martina Benedetti, Mamoona Arshad, Giuseppe Verlato, Vincenzo Villanacci

Background: Potential coeliac disease is an increasingly diagnosed condition, and the dilemma whether start a gluten-free diet is still unsolved.

Aims: We hypothesized that an exaggerated enterocyte turnover is responsible for an impairment of gut function leading to the development of symptoms and/or progression to villous atrophy.

Methods: The proliferation and apoptotic rates of duodenal enterocytes, assessed by anti-Ki-67 and -Caspase-3 antibodies at immunohistochemistry, of 36 adult patients with potential coeliac disease were compared to those found in a group of 32 active coeliac patients and a group of 31 controls. Statistics was computed by Fisher's exact test, Wilcoxon-Mann-Whitney rank-sum test, and Kruskal-Wallis test as appropriate, post-hoc analysis was performed by Dunn's test with Bonferroni correction.

Results: Nearly all patients with potential coeliac disease reported symptoms (31/36 = 86.1 %), and four out 36 developed active disease over time. A significant increase of enterocyte proliferation (p = 0.042), but not of apoptosis (p = 0.514), in comparison with control subjects was found. Notably, a significant correlation between Ki-67 expression and the progression to villous atrophy (p = 0.015) was evident.

Conclusions: The maintenance of mucosal architecture in potential coeliac disease is due to enterocyte hyper-proliferation that causes the presence of immature cells on the villous lining and correlates with the development of villous atrophy.

背景:潜在的乳糜泻是一种越来越多的诊断疾病,是否开始无谷蛋白饮食的困境仍然没有得到解决。目的:我们假设过度的肠细胞转换是肠道功能受损的原因,导致症状的发展和/或绒毛萎缩的进展。方法:采用免疫组化抗ki -67和-Caspase-3抗体评估36例潜在乳糜泻成年患者的十二指肠肠细胞增殖和凋亡率,与32例活动性乳糜泻患者和31例对照组进行比较。统计量采用Fisher精确检验、Wilcoxon-Mann-Whitney秩和检验,酌情采用Kruskal-Wallis检验,事后分析采用Dunn检验,Bonferroni校正。结果:几乎所有的潜在乳糜泻患者都报告了症状(31/36 = 86.1%),36例患者中有4例随着时间的推移发展为活动性疾病。与对照组相比,肠细胞增殖显著增加(p = 0.042),但细胞凋亡无显著增加(p = 0.514)。值得注意的是,Ki-67的表达与绒毛萎缩的进展有显著的相关性(p = 0.015)。结论:在潜在的乳糜泻中,黏膜结构的维持是由于肠细胞过度增殖,导致绒毛衬里存在未成熟细胞,并与绒毛萎缩的发展相关。
{"title":"Enterocyte proliferation as a new biomarker in potential coeliac disease.","authors":"Rachele Ciccocioppo, Cinzia D'Agate, Maria Vittoria Galli, Anna Macchioni, Giuseppe Broggi, Valeria Zuliani, Luca Frulloni, Fabio Luciani, Mattia Bugatti, Martina Benedetti, Mamoona Arshad, Giuseppe Verlato, Vincenzo Villanacci","doi":"10.1016/j.dld.2025.12.011","DOIUrl":"https://doi.org/10.1016/j.dld.2025.12.011","url":null,"abstract":"<p><strong>Background: </strong>Potential coeliac disease is an increasingly diagnosed condition, and the dilemma whether start a gluten-free diet is still unsolved.</p><p><strong>Aims: </strong>We hypothesized that an exaggerated enterocyte turnover is responsible for an impairment of gut function leading to the development of symptoms and/or progression to villous atrophy.</p><p><strong>Methods: </strong>The proliferation and apoptotic rates of duodenal enterocytes, assessed by anti-Ki-67 and -Caspase-3 antibodies at immunohistochemistry, of 36 adult patients with potential coeliac disease were compared to those found in a group of 32 active coeliac patients and a group of 31 controls. Statistics was computed by Fisher's exact test, Wilcoxon-Mann-Whitney rank-sum test, and Kruskal-Wallis test as appropriate, post-hoc analysis was performed by Dunn's test with Bonferroni correction.</p><p><strong>Results: </strong>Nearly all patients with potential coeliac disease reported symptoms (31/36 = 86.1 %), and four out 36 developed active disease over time. A significant increase of enterocyte proliferation (p = 0.042), but not of apoptosis (p = 0.514), in comparison with control subjects was found. Notably, a significant correlation between Ki-67 expression and the progression to villous atrophy (p = 0.015) was evident.</p><p><strong>Conclusions: </strong>The maintenance of mucosal architecture in potential coeliac disease is due to enterocyte hyper-proliferation that causes the presence of immature cells on the villous lining and correlates with the development of villous atrophy.</p>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments ASAP评分可预测局部治疗放射学完全缓解后早期HCC复发。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-03 DOI: 10.1016/j.dld.2025.12.018
Lorenzo Canova , Massimo Iavarone , Eleonora Alimenti , Mariangela Bruccoleri , Lorenzo Argiento , Riccardo Perbellini , Floriana Facchetti , Sara Uceda Renteria , Roberta D’Ambrosio , Elisabetta Degasperi , Anna Maria Ierardi , Angelo Sangiovanni , Matteo Vidali , Pietro Lampertico

Background and Aims

The ASAP algorithm incorporating Age, Sex, Alpha-fetoprotein (AFP), and prothrombin induced by vitamin K absence/antagonist II (PIVKA-II) has been shown to predict hepatocellular carcinoma (HCC) development. Our study evaluated the prognostic value of ASAP for early HCC recurrence after complete radiological response (CR) to locoregional therapy.

Methods

This single-center study enrolled patients with newly diagnosed HCC who achieved CR by ablation (MWTA) or chemoembolization (TACE) and available serum samples on the day of treatment. CR was evaluated by CT-scan 1 month after treatment. PIVKA-II and AFP levels were measured using Fujirebio assays. Patients were followed up every three months until recurrence, death, or last follow-up.

Results

127 patients with HCC (median age 66 years, 79 % male, 79 % with viral etiology) who achieved CR were enrolled. At time of treatment, median AFP and PIVKA-II levels were 6.6 ng/mL and 144 mAU/mL, respectively, while median ASAP score was 0.60. During follow-up, HCC recurred in 72 (56.7 %) patients (63 within 24 months, early recurrence). ASAP score was the sole independent predictor of early recurrence [HR 2.57 (95 % CI 1.50-4.40), p=0.001] and its new cutoff of 0.797 (AUC 66 %, sensitivity 57 %, specificity 75 %) outperformed other scores and biomarkers.

Conclusions

The ASAP score accurately predicted early HCC recurrence post-CR, warranting further validation.
背景和目的:结合年龄、性别、甲胎蛋白(AFP)和维生素K缺失/拮抗剂II (PIVKA-II)诱导的凝血酶原的ASAP算法已被证明可以预测肝细胞癌(HCC)的发展。我们的研究评估了ASAP对局部治疗完全放射反应(CR)后早期HCC复发的预后价值。方法:这项单中心研究纳入了通过消融(MWTA)或化疗栓塞(TACE)和治疗当天可用血清样本达到CR的新诊断HCC患者。治疗1个月后通过ct扫描评估CR。采用Fujirebio法测定PIVKA-II和AFP水平。患者每3个月随访一次,直至复发、死亡或最后一次随访。结果:纳入了127例达到CR的HCC患者(中位年龄66岁,79%为男性,79%为病毒病因)。治疗时,AFP和PIVKA-II水平中位数分别为6.6 ng/mL和144 mAU/mL, ASAP评分中位数为0.60。随访期间,72例(56.7%)患者HCC复发(63例24个月内早期复发)。ASAP评分是早期复发的唯一独立预测因子[HR 2.57 (95% CI 1.50-4.40), p=0.001],其新截止值0.797 (AUC 66%,敏感性57%,特异性75%)优于其他评分和生物标志物。结论:ASAP评分能准确预测HCC术后早期复发,值得进一步验证。
{"title":"ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments","authors":"Lorenzo Canova ,&nbsp;Massimo Iavarone ,&nbsp;Eleonora Alimenti ,&nbsp;Mariangela Bruccoleri ,&nbsp;Lorenzo Argiento ,&nbsp;Riccardo Perbellini ,&nbsp;Floriana Facchetti ,&nbsp;Sara Uceda Renteria ,&nbsp;Roberta D’Ambrosio ,&nbsp;Elisabetta Degasperi ,&nbsp;Anna Maria Ierardi ,&nbsp;Angelo Sangiovanni ,&nbsp;Matteo Vidali ,&nbsp;Pietro Lampertico","doi":"10.1016/j.dld.2025.12.018","DOIUrl":"10.1016/j.dld.2025.12.018","url":null,"abstract":"<div><h3>Background and Aims</h3><div>The ASAP algorithm incorporating Age, Sex, Alpha-fetoprotein (AFP), and prothrombin induced by vitamin K absence/antagonist II (PIVKA-II) has been shown to predict hepatocellular carcinoma (HCC) development. Our study evaluated the prognostic value of ASAP for early HCC recurrence after complete radiological response (CR) to locoregional therapy.</div></div><div><h3>Methods</h3><div>This single-center study enrolled patients with newly diagnosed HCC who achieved CR by ablation (MWTA) or chemoembolization (TACE) and available serum samples on the day of treatment. CR was evaluated by CT-scan 1 month after treatment. PIVKA-II and AFP levels were measured using Fujirebio assays. Patients were followed up every three months until recurrence, death, or last follow-up.</div></div><div><h3>Results</h3><div>127 patients with HCC (median age 66 years, 79 % male, 79 % with viral etiology) who achieved CR were enrolled. At time of treatment, median AFP and PIVKA-II levels were 6.6 ng/mL and 144 mAU/mL, respectively, while median ASAP score was 0.60. During follow-up, HCC recurred in 72 (56.7 %) patients (63 within 24 months, early recurrence). ASAP score was the sole independent predictor of early recurrence [HR 2.57 (95 % CI 1.50-4.40), p=0.001] and its new cutoff of 0.797 (AUC 66 %, sensitivity 57 %, specificity 75 %) outperformed other scores and biomarkers.</div></div><div><h3>Conclusions</h3><div>The ASAP score accurately predicted early HCC recurrence post-CR, warranting further validation.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"58 2","pages":"Pages 241-249"},"PeriodicalIF":3.8,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral butyrate in IBD: From enterotype stratification to a multi-omic and long-term clinical dialogue. 口服丁酸治疗IBD:从肠型分层到多组学和长期临床对话。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-02 DOI: 10.1016/j.dld.2025.12.020
Yan An, Pengfei E
{"title":"Oral butyrate in IBD: From enterotype stratification to a multi-omic and long-term clinical dialogue.","authors":"Yan An, Pengfei E","doi":"10.1016/j.dld.2025.12.020","DOIUrl":"https://doi.org/10.1016/j.dld.2025.12.020","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Helicobacter pylori multiplex serology in patients with autoimmune atrophic gastritis negative for Helicobacter pylori at histology: A case-control study 组织学上幽门螺杆菌阴性的自身免疫性萎缩性胃炎患者的多重幽门螺杆菌血清学:一项病例对照研究。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-02 DOI: 10.1016/j.dld.2025.12.002
Marica Vavallo , Julia Butt , Sophia Cingolani , Giulio Cozza , Francesco Paolo Schiavone , Emanuele Dilaghi , Laura Belloni , Matteo Franchitto , Bruno Annibale , Tim Waterboer , Edith Lahner

Background

Autoimmune atrophic gastritis (AAG) is an immune-mediated disorder affecting the gastric oxyntic mucosa. Two pathogenetic models are proposed: a pure autoimmune disorder or gastric autoimmunity triggered by Helicobacter pylori (Hp)-infection. In AAG, histological diagnosis of Hp may be challenging and serology can help assess exposure to Hp-infection. This study aimed to determine seroreactivity to Hp-antigens in AAG patients by using Hp-multiplex serology assay.

Methods

A single-centre case-control study on 178 adults: 75 patients with serological and histological AAG diagnosis, 25 controls with histologically Hp-positive-non-atrophic gastritis (Ctr-NAG-Hp+) and 78 subjects with a healthy stomach (Ctr-HS). Sera were analysed using Hp-multiplex serology assay allowing simultaneous detection of antibodies to 13 Hp-proteins. Overall positivity cutoff: seroreactivity to more than 3 Hp-antigens.

Results

The number of seroreactive Hp-antigens was higher in AAG than in Ctr-HS(mean±SEM 2.2±0.3 vs 1.4±0.22,p=0.02) and lower than in Ctr-NAG-Hp+ patients (mean±SEM 5.4±0.5,p<0.001).Overall Hp-seropositivity in AAG was two-fold higher than in Ctr-HS but not statistically significant (21.1% vs 10.3%,p=0.06) and lower than in Ctr-NAG-Hp+(80%,p<0.0001). Complete absence of seroreactivity was similar in AAG and Ctr-HS (29.3% vs 38.5%, p=0.23) and significantly higher than in Ctr-NAG-Hp+ (4%, p=0.009). Main immunogenic Hp-proteins were HP0010(GroEL),HP1098(HcpC),HP0695(HyuA),HP0875(Catalase),HP1564,HP0547(CagA) and HP0243(NapA) with seroreactivity in >50% of AAG patients.

Conclusions

By Hp-multiplex serology, 30% of histologically Hp-negative AAG pts had no seroreactivity, likely belonging to the pure AAG type. Conversely, 20% of AAG pts showed Hp exposure, indicating that infection might have triggered gastric autoimmunity. The remaining AAG patients showed seroreactivity below cut-off for seropositivity and thus not definitively categorisable by this approach.
背景:自身免疫性萎缩性胃炎(AAG)是一种影响胃氧合粘膜的免疫介导性疾病。提出了两种发病模式:单纯的自身免疫性疾病或幽门螺杆菌感染引发的胃自身免疫。在AAG中,Hp的组织学诊断可能具有挑战性,血清学可以帮助评估Hp感染暴露。本研究旨在采用hp -复合血清学方法测定AAG患者对hp抗原的血清反应性。方法:对178名成人进行单中心病例对照研究:75例血清学和组织学诊断为AAG的患者,25例组织学上hp阳性-非萎缩性胃炎(cr - nag - hp +)对照,78例健康胃(cr - hs)对照。采用hp多重血清学方法分析血清,同时检测13种hp蛋白的抗体。总体阳性切断:对3种以上hp抗原有血清反应。结果:AAG患者血清反应性hp抗原数量高于cr - hs患者(平均±SEM 2.2±0.3 vs 1.4±0.22,p=0.02),低于cr - nag - hp +患者(平均±SEM 5.4±0.5,p = 50%)。结论:hp -多重血清学结果显示,30%组织学hp阴性的AAG患者无血清反应,可能属于纯AAG型。相反,20%的AAG患者显示Hp暴露,表明感染可能引发了胃自身免疫。其余AAG患者的血清反应低于血清阳性的临界值,因此不能通过该方法明确分类。
{"title":"Helicobacter pylori multiplex serology in patients with autoimmune atrophic gastritis negative for Helicobacter pylori at histology: A case-control study","authors":"Marica Vavallo ,&nbsp;Julia Butt ,&nbsp;Sophia Cingolani ,&nbsp;Giulio Cozza ,&nbsp;Francesco Paolo Schiavone ,&nbsp;Emanuele Dilaghi ,&nbsp;Laura Belloni ,&nbsp;Matteo Franchitto ,&nbsp;Bruno Annibale ,&nbsp;Tim Waterboer ,&nbsp;Edith Lahner","doi":"10.1016/j.dld.2025.12.002","DOIUrl":"10.1016/j.dld.2025.12.002","url":null,"abstract":"<div><h3>Background</h3><div>Autoimmune atrophic gastritis (AAG) is an immune-mediated disorder affecting the gastric oxyntic mucosa. Two pathogenetic models are proposed: a pure autoimmune disorder or gastric autoimmunity triggered by <em>Helicobacter pylori</em> (Hp)-infection. In AAG, histological diagnosis of Hp may be challenging and serology can help assess exposure to Hp-infection. This study aimed to determine seroreactivity to Hp-antigens in AAG patients by using Hp-multiplex serology assay.</div></div><div><h3>Methods</h3><div>A single-centre case-control study on 178 adults: 75 patients with serological and histological AAG diagnosis, 25 controls with histologically Hp-positive-non-atrophic gastritis (Ctr-NAG-Hp+) and 78 subjects with a healthy stomach (Ctr-HS). Sera were analysed using Hp-multiplex serology assay allowing simultaneous detection of antibodies to 13 Hp-proteins. Overall positivity cutoff: seroreactivity to more than 3 Hp-antigens.</div></div><div><h3>Results</h3><div>The number of seroreactive Hp-antigens was higher in AAG than in Ctr-HS(mean±SEM 2.2±0.3 vs 1.4±0.22,p=0.02) and lower than in Ctr-NAG-Hp+ patients (mean±SEM 5.4±0.5,p&lt;0.001).Overall Hp-seropositivity in AAG was two-fold higher than in Ctr-HS but not statistically significant (21.1% vs 10.3%,p=0.06) and lower than in Ctr-NAG-Hp+(80%,p&lt;0.0001). Complete absence of seroreactivity was similar in AAG and Ctr-HS (29.3% vs 38.5%, p=0.23) and significantly higher than in Ctr-NAG-Hp+ (4%, p=0.009). Main immunogenic Hp-proteins were HP0010(GroEL),HP1098(HcpC),HP0695(HyuA),HP0875(Catalase),HP1564,HP0547(CagA) and HP0243(NapA) with seroreactivity in &gt;50% of AAG patients.</div></div><div><h3>Conclusions</h3><div>By Hp-multiplex serology, 30% of histologically Hp-negative AAG pts had no seroreactivity, likely belonging to the pure AAG type. Conversely, 20% of AAG pts showed Hp exposure, indicating that infection might have triggered gastric autoimmunity. The remaining AAG patients showed seroreactivity below cut-off for seropositivity and thus not definitively categorisable by this approach.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"58 2","pages":"Pages 212-219"},"PeriodicalIF":3.8,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The unbearable cost of being gluten-free: rethinking celiac disease screening. 无谷蛋白食品难以承受的成本:重新思考乳糜泻筛查。
IF 3.8 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2026-01-02 DOI: 10.1016/j.dld.2025.12.009
Ruggiero Francavilla, Vanessa Nadia Dargenio, Stefania Paola Castellaneta, Fernanda Cristofori
{"title":"The unbearable cost of being gluten-free: rethinking celiac disease screening.","authors":"Ruggiero Francavilla, Vanessa Nadia Dargenio, Stefania Paola Castellaneta, Fernanda Cristofori","doi":"10.1016/j.dld.2025.12.009","DOIUrl":"https://doi.org/10.1016/j.dld.2025.12.009","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive and Liver Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1